TY - JOUR
T1 - Update on Atopic Dermatitis
T2 - Diagnosis, Severity Assessment, and Treatment Selection
AU - Fishbein, Anna B.
AU - Silverberg, Jonathan I.
AU - Wilson, Eve J.
AU - Ong, Peck Y.
N1 - Funding Information:
This work was supported by an unrestricted educational grant from Sanofi and Regeneron Pharmaceuticals, Inc. Conflicts of interest: J. I. Silverberg has served as a consultant for AbbVie, AnaptysBio, Asana BioSciences, Eli Lilly, Galderma, GlaxoSmithKline, Kiniksa, Leo Pharma, and Sanofi and Regeneron Pharmaceuticals. P. Y. Ong has served as a consultant for Pfizer, Inc.; and has done contract research with Regeneron Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have disclosed no relevant financial relationships.
PY - 2020/1
Y1 - 2020/1
N2 - Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting children and adults. The intense pruritus and rash can be debilitating, significantly impairing quality of life. Until recently, treatment was largely nonspecific and, in severe disease, sometimes ineffective and/or fraught with many side effects. Now, multiple agents targeting specific disease pathways are available or in development. Two new therapies, crisaborole and dupilumab, have become available since 2016, and dupilumab has dramatically improved outcomes for adults with severe AD. This article provides an overview of AD, including strategies for differential diagnosis and assessment of disease severity to guide treatment selection. Key clinical trials for crisaborole and dupilumab are reviewed, and other targeted treatments now in development are summarized. Two cases, representing childhood-onset and adult-onset AD, are discussed to provide clinical context for diagnosis, severity assessment, and treatment selection and outcomes.
AB - Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting children and adults. The intense pruritus and rash can be debilitating, significantly impairing quality of life. Until recently, treatment was largely nonspecific and, in severe disease, sometimes ineffective and/or fraught with many side effects. Now, multiple agents targeting specific disease pathways are available or in development. Two new therapies, crisaborole and dupilumab, have become available since 2016, and dupilumab has dramatically improved outcomes for adults with severe AD. This article provides an overview of AD, including strategies for differential diagnosis and assessment of disease severity to guide treatment selection. Key clinical trials for crisaborole and dupilumab are reviewed, and other targeted treatments now in development are summarized. Two cases, representing childhood-onset and adult-onset AD, are discussed to provide clinical context for diagnosis, severity assessment, and treatment selection and outcomes.
KW - Adult onset
KW - Atopic dermatitis
KW - Crisaborole
KW - Differential diagnosis
KW - Dupilumab
KW - Eczema
KW - Infant onset
KW - Severity assessment
UR - http://www.scopus.com/inward/record.url?scp=85077085295&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077085295&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.06.044
DO - 10.1016/j.jaip.2019.06.044
M3 - Review article
C2 - 31474543
AN - SCOPUS:85077085295
VL - 8
SP - 91
EP - 101
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 1
ER -